



Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

APR 11 2001

Ms. Feng-Yu Lee
Vice President of Quality System
Forefront Diagnostics, Inc.
23561 Ridge Route Drive, Suite D
Laguna Hills, CA 92653

Re: 510(k) NUMBER: K003546

Trade/Device Names: InstaCheck® Multi-Drug Screen Panel THC/COC, MOR 300/MET
1000/MTD, AMP/BAR/BZO Test
InstaCheck® Multi-Drug Screen Panel THC/COC/PCP, MOR
2000/MET 1000, AMP/BAR/BZO Test
InstaCheck® Multi-Drug Screen Panel THC/COC/PCP, MOR
300/MET 1000, AMP/BAR/BZO Test
InstaCheck® Multi-Drug Screen Panel THC/COC/PCP, MOR
300/MET 1000/MTD, AMP/BAR/BZO Test

Regulation Number: 862.3100, 862.3610, 862.3150, 862.3170, 862.3870, 862.3250,
862.3640, 862.3620

Regulatory Class: II

Product Code: DKZ, DJC, DIS, JXM, LDJ, DIO, DPK, LCM, DJR

Dated: February 27, 2001

Received: March 1, 2001

Dear Ms.Lee:

This letter corrects the original substantially equivalent letter dated April 5, 2001, regarding the omission of Trade/Device Names and the unsigned Indications for Use for each of those Trade/Device Names.

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895.

A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or at (301) 443-6597, or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive, slightly slanted style.

Steven I. Gutman, M.D., M.B.A.
Director
Division of Clinical Laboratory Devices
Office of Device Evaluation
Center for Devices and Radiological Health


510(k) Number (if known): K003546Device Name: InstaCheck® Multi-Drug Screen Panel THC/COC, MOR 300/MET
1000/MTD, AMP/BAR/BZO Test

Indications For Use:

The Forefront Diagnostics InstaCheck® Multi-Drug Screen Panel THC/COC, MOR 300/MET 1000/MTD, AMP/BAR/BZO Test is an *in vitro* screen test for the rapid detection of 11-nor- Δ^9 -Tetrahydrocannabinol-9-carboxylic acid, Cocaine and its metabolite - Benzoylecgonine, Morphine, Methamphetamine, Methadone, Amphetamine, Barbiturates and its metabolite - Secobarbital, Benzodiazepines and its metabolite - Oxazepam, in human urine at the following concentrations.

THC	11-nor- Δ^9 -Tetrahydrocannabinol-9-carboxylic acid	50 ng/ml
COC	Benzoylecgonine	300 ng/ml
MOR	Morphine	300 ng/ml
MET	Methamphetamine	1000 ng/ml
MTD	Methadone	300 ng/ml
AMP	Amphetamine	1000 ng/ml
BAR	Secobarbital	300 ng/ml
BZO	Oxazepam	300 ng/ml

The test kit is used to obtain a visual, qualitative result and is intended for professional use. It is not intended for over the counter sale to lay persons.


(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K003546

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓
(Per 21 CFR 801.109)

OR

Over-The-Counter Use _____

(Optional Format 1-2-96)

510(k) Number (if known): K003546Device Name: InstaCheck® Multi-Drug Screen Panel THC/COC/PCP, MOR 2000/MET 1000, AMP/BAR/BZO Test

Indications For Use:

The Forefront Diagnostics InstaCheck® Multi-Drug Screen Panel THC/COC/PCP, MOR 2000/MET 1000, AMP/BAR/BZO Test is an *in vitro* screen test for the rapid detection of 11-nor- Δ^9 -Tetrahydrocannabinol-9-carboxylic acid, Cocaine and its metabolite - Benzoylecgonine, PCP, Morphine, Methamphetamine, Amphetamine, Barbiturates and its metabolite - Secobarbital, Benzodiazepines and its metabolite - Oxazepam, in human urine at the following concentrations.

THC	11-nor- Δ^9 -Tetrahydrocannabinol-9-carboxylic acid	50 ng/ml
COC	Benzoylecgonine	300 ng/ml
PCP	Phencyclidine	25 ng/ml
MOR	Morphine	2000 ng/ml
MET	Methamphetamine	1000 ng/ml
AMP	Amphetamine	1000 ng/ml
BAR	Secobarbital	300 ng/ml
BZO	Oxazepam	300 ng/ml

The test kit is used to obtain a visual, qualitative result and is intended for professional use. It is not intended for over the counter sale to lay persons.

Ann Dausbich for Jean Cooper

(Division Sign-Off)

Division of Clinical Laboratory Devices

510(k) Number K003546

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓
(Per 21 CFR 801.109)

OR

Over-The-Counter Use _____

(Optional Format 1-2-96)

Page _____ of _____

510(k) Number (if known): K003546

Device Name: InstaCheck® Multi-Drug Screen Panel THC/COC/PCP, MOR 300/MET 1000, AMP/BAR/BZO Test

Indications For Use:

The Forefront Diagnostics InstaCheck® Multi-Drug Screen Panel THC/COC/PCP, MOR 300/MET 1000, AMP/BAR/BZO Test is an *in vitro* screen test for the rapid detection of 11-nor- Δ^9 -Tetrahydrocannabinol-9-carboxylic acid, Cocaine and its metabolite - Benzoylcegonine, PCP, Morphine, Methamphetamine, Amphetamine, Barbiturates and its metabolite - Secobarbital, Benzodiazepines and its metabolite - Oxazepam, in human urine at the following concentrations.

THC	11-nor- Δ^9 -Tetrahydrocannabinol-9-carboxylic acid	50 ng/ml
COC	Benzoylcegonine	300 ng/ml
PCP	Phencyclidine	25 ng/ml
MOR	Morphine	300 ng/ml
MET	Methamphetamine	1000 ng/ml
AMP	Amphetamine	1000 ng/ml
BAR	Secobarbital	300 ng/ml
BZO	Oxazepam	300 ng/ml

The test kit is used to obtain a visual, qualitative result and is intended for professional use. It is not intended for over the counter sale to lay persons.

Sub Director for Jean Cooper

(Division Sign-Off)

Division of Clinical Laboratory Devices

510(k) Number K003546

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓
(Per 21 CFR 801.109)

OR

Over-The-Counter Use _____

(Optional Format 1-2-96)

510(k) Number (if known):

K003546

Device Name:

InstaCheck® Multi-Drug Screen Panel THC/COC/PCP, MOR 300/MET
1000/MTD, AMP/BAR/BZO Test

Indications For Use:

The Forefront Diagnostics InstaCheck® Multi-Drug Screen Panel THC/COC/PCP, MOR 300/MET 1000/MTD, AMP/BAR/BZO Test is an *in vitro* screen test for the rapid detection of 11-nor- Δ^9 -Tetrahydrocannabinol-9-carboxylic acid, Cocaine and its metabolite-Benzoyllecgonine, PCP, Morphine, Methamphetamine, Methadone, Amphetamine, Barbiturates and its metabolite - Secobarbital, Benzodiazepines and its metabolite - Oxazepam, in human urine at the following concentrations.

THC	11-nor- Δ^9 -Tetrahydrocannabinol-9-carboxylic acid	50 ng/ml
COC	Benzoyllecgonine	300 ng/ml
PCP	Phencyclidine	25 ng/ml
MOR	Morphine	300 ng/ml
MET	Methamphetamine	1000 ng/ml
MTD	Methadone	300 ng/ml
AMP	Amphetamine	1000 ng/ml
BAR	Secobarbital	300 ng/ml
BZO	Oxazepam	300 ng/ml

The test kit is used to obtain a visual, qualitative result and is intended for professional use. It is not intended for over the counter sale to lay persons.

Ans. Danilof for Jean Cooper

(Division Sign-Off)

Division of Clinical Laboratory Devices

510(k) Number _____

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ☒
(Per 21 CFR 801.109)

OR

Over-The-Counter Use _____

(Optional Format 1-2-96)